TDP-43 and frontotemporal dementia

Current Neurology and Neuroscience Reports

Volumn 9, Issue 5, 2009, Pages 353-358

  Hu, William T ^a   Grossman, Murray ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMATIN MODIFYING PROTEIN 2B; COPPER ZINC SUPEROXIDE DISMUTASE; MEMBRANE PROTEIN; PROGRANULIN; SURVIVAL MOTOR NEURON PROTEIN; TAR DNA BINDING PROTEIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; AMYOTROPHIC LATERAL SCLEROSIS; CHROMOSOME; CLINICAL FEATURE; CODON; COMORBIDITY; EXON; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; IMMUNOREACTIVITY; PATHOGENESIS; PRIMARY PROGRESSIVE APHASIA; PROGRESSIVE NONFLUENT APHASIA; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SEMANTIC DEMENTIA; UBIQUITINATION;

BIOLOGICAL MARKERS; BRAIN; DEMENTIA; DNA-BINDING PROTEINS; HUMANS; INCLUSION BODIES; MUTATION; NEURONS;

EID: 68449086262     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-009-0052-3     Document Type: Review

References (54)

1. Neary D, Snowden JS, Gustafson L, et al.: Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 1998, 51:1546-1554.
2. McKhann GM, Albert MS, Grossman M, et al.: Clinical and pathological diagnosis of frontotemporal dementia: Report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 2001, 58:1803-1809.
3. Forman MS, Farmer J, Johnson JK, et al.: Frontotemporal dementia: clinicopathological correlations. Ann Neurol 2006, 59:952-962.
4. Mackenzie IR, Neumann M, Bigio EH, et al.: Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: Consensus recommendations. Acta Neuropathol 2009, 117:15-18.
5. Neumann M, Sampathu DM, Kwong LK, et al.: Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314:130-133.
6. Buratti E, Dork T, Zuccato E, et al.: Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J 2001, 20:1774-1784.
7. Rosso SM, Donker Kaat L, Baks T, et al.: Frontotemporal dementia in the Netherlands: Patient characteristics and prevalence estimates from a population-based study. Brain 2003, 126:2016-2022.
8. Josephs KA, Petersen RC, Knopman DS, et al.: Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006, 66:41-48.
9. Hu WT, Seelaar H, Josephs KA, et al.: Survival profiles of patients with frontotemporal dementia and motor neuron disease. Arch Neurol (in press).
10. Geser F, Martinez-Lage M, Robinson J, et al.: Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 2009, 66:180-189.
11. Snowden J, Neary D, Mann D: FContotemporal lobar degeneration: clinical and pathological relationships. Acta Neuropathol 2007, 114:31-38.
12. Knibb JA, Xuereb JH, Patterson K, Hodges JR: Clinical and pathological characterization of progressive aphasia. Ann Neurol 2006, 59:156-165.
13. Gorno-Tempini ML, Brambati SM, Ginex V, et al.: The logopenic/ phonological variant of primary progressive aphasia. Neurology 2008, 71:1227-1234.
14. Mesulam M, Wicklund A, Johnson N, et al.: Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol 2008, 63:709-719.
15. Hodges JR, Davies RR, Xuereb JH, et al.: Clinicopathological correlates in frontotemporal dementia. Ann Neurol 2004, 56:399-406.
16. Hu WT, Mandrekar JN, Parisi JE, et al.: Clinical features of pathologic subtypes of behavioral - variant frontotemporal dementia. Arch Neurol 2007, 64:1611-1616.
17. Whitwell JL, Jack CR Jr, Senjem ML, et al.: MRI correlates of protein deposition and disease severity in postmortem frontotemporal lobar degeneration. Neurodegener Dis 2009, 6:106-117.
18. Kim EJ, Rabinovici GD, Seeley WW, et al.: Patterns of MRI atrophy in tau positive and ubiquitin positive frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 2007, 78:1375-1378.
19. Vucic S, Kierna MC: Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis. Curr Mol Med 2009, 9:255-272.
20. Mackenzie IR, Bigio EH, Ince PG, et al.: Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007, 61:427-434.
21. Sreedharan J, Blair IP, Tripathi VB, et al.: TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008, 319:1668-1672.
22. Van Deerlin VM, Leverenz JB, Bekris LM, et al.: TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: A genetic and histopathological analysis. Lancet Neurol 2008, 7:409-416.
23. Yokoseki A, Shiga A, Tan CF, et al.: TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann Neurol 2008, 63:538-542.
24. Kabashi E, Valdmanis PN, Dion P, et al.: TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 2008, 40:572-574.
25. Winton MJ, Van Deerlin VM, Kwong LK, et al.: A90V TDP-43 variant results in the aberrant localization of TDP-43 in vitro. FEBS Lett 2008, 582:2252-2256.
26. Benajiba L, Le Ber I, Camuzat A, et al.: TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann Neurol 2009, 65:470-473.
27. Kuhnlein P, Sperfeld AD, Vanmassenhove B, et al.: Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations. Arch Neurol 2008; 65:1185-1189.
28. Corrado L, Ratti A, Gellera C, et al.: High frequency of TARDBP gene mutations in Italian patients with amyotrophic lateral sclerosis. Hum Mutat 2009, 30:688-694.
29. Baker M, Mackenzie IR, Pickering-Brown SM, et al.: Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006, 442:916-919.
30. Cruts M, Gijselinck I, van der Zee J, et al.: Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006, 442:920-924.
31. He Z, Ismail A, Kriazhev L, et al.: Progranulin (PC-cellderived growth factor/acrogranin) regulates invasion and cell survival. Cancer Res 2002, 62:5590-5596.
32. Zhu J, Nathan C, Jin W, et al.: Conversion of proepithelin to epithelins: Roles of SLPI and elastase in host defense and wound repair. Cell 2002, 111:867-878.
33. Coppola G, Karydas A, Rademakers R, et al.: Gene expression study on peripheral blood identifies progranulin mutations. Ann Neurol 2008, 64:92-96.
34. Sleegers K, Brouwers N, Van Damme P, et al.: Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann Neurol 2009, 65:603-609.
35. Rademakers R, Eriksen JL, Baker M, et al.: Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet 2008, 17:3631-3642.
36. Chen-Plotkin AS, Geser F, Plotkin JB, et al.: Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration. Hum Mol Genet 2008, 17:1349-1362.
37. Boeve BF, Baker M, Dickson DW, et al.: Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study. Brain 2006, 129:3103-3114.
38. Le Ber I, Camuzat A, Hannequin D, et al.: Phenotype variability in progranulin mutation carriers: A clinical, neuropsychological, imaging and genetic study. Brain 2008, 131:732-746.
39. Josephs KA, Ahmed Z, Katsuse O, et al.: Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J Neuropathol Exp Neurol 2007, 66:142-151.
40. Forman MS, Mackenzie IR, Cairns NJ, et al.: Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. J Neuropathol Exp Neurol 2006, 65:571-581.
41. van der Zee J, Urwin H, Engelborghs S, et al.: CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro. Hum Mol Genet 2008, 17:313-322.
42. Skibinski G, Parkinson NJ, Brown JM, et al.: Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet 2005, 37:806-808.
43. Sampathu DM, Neumann M, Kwong LK, et al.: Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol 2006, 169:1343-1352.
44. Grossman M, Wood EM, Moore P, et al.: TDP-43 pathologic lesions and clinical phenotype in frontotemporal lobar degeneration with ubiquitin-positive inclusions. Arch Neurol 2007, 64:1449-1454.
45. Igaz LM, Kwong LK, Chen-Plotkin A, et al.: Expression of TDP-43 C-terminal fragments in vitro recapitulates pathological features of TDP-43 proteinopathies. J Biol Chem 2009, 284:8516-8524.
46. Tatom JB, Wang DB, Dayton RD, et al.: Mimicking aspects of frontotemporal lobar degeneration and Lou Gehrig's disease in rats via TDP-43 overexpression. Mol Ther 2009, 17:607-613.
47. Bose JK, Wang IF, Hung L, et al.: TDP-43 overexpression enhances exon 7 inclusion during the survival of motor neuron pre-mRNA splicing. J Biol Chem 2008, 283:28852-28859.
48. Mackenzie IR, Foti D, Woulfe J, Hurwitz TA: Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions. Brain 2008, 131:1282-1293.
49. Josephs KA, Lin WL, Ahmed Z, et al.: Frontotemporal lobar degeneration with ubiquitin-positive, but TDP-43-negative inclusions. Acta Neuropathol 2008, 116:159-167.
50. Roeber S, Mackenzie IR, Kretzschmar HA, Neumann M: TDP-43-negative FTLD-U is a significant new clinicopathological subtype of FTLD. Acta Neuropathol 2008, 116:147-157.
51. Bian H, Van Swieten JC, Leight S, et al.: CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 2008, 70:1827-1835.
52. Foulds P, McAuley E, Gibbons L, et al.: TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration. Acta Neuropathol 2008, 116:141-146.
53. Kasai T, Tokuda T, Ishigami N, et al.: Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol 2009, 117: 55-62.
54. Mitchell RM, Freeman WM, Randazzo WT, et al.: A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology 2009, 72:14-19.